Send to

Choose Destination
Clin Nephrol. 1990 Apr;33(4):200-2.

The use of subcutaneous erythropoietin in CAPD patients.

Author information

Department of Medicine, University of Pittsburgh, PA.


There is little data available on the use of erythropoietin in CAPD patients. The available pharmacokinetic and clinical data suggest that a low dose of subcutaneous erythropoietin might be effective. Seven CAPD patients, without active malignancy or infection, self-administered erythropoietin, 2,000 units (a mean of 32 units/kg) subcutaneously, three times a week. The Hct rose from 23% to 31% in a mean treatment time of 7 weeks, or a rate of rise of 1.2% per week. Three of the patients had previously been transfusion dependent. One of these patients and two additional had iron overload (ferritin level greater than 2,000 ng/ml). The drug was paid for by Medicaid (two patients) or private insurance, with the patient paying the uncovered portion, generally 20%. Side effects were minimal. Low dose subcutaneous erythropoietin is effective in CAPD patients.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center